TECX Stock Analysis: Buy, Sell, or Hold?
TECX - Tectonic Therapeutic, Inc. Common Stock
$37.63
1.58 (4.38%)
▲
5d:
+7.79%
30d:
+19.04%
90d:
+31.94%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When TECX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TECX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TECX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TECX is currently trading at $37.63, which is considered extended relative to its 30-day fair value range of $29.28 to $34.92.
Technical Outlook: Technically, TECX is in a uptrend. The price is approaching resistance at $38.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: TECX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $77.56 (+106.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TECX is in a uptrend. The price is approaching resistance at $38.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: TECX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $77.56 (+106.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$29.28 -
$34.92
Company Quality Score
30/100
(SELL)
Options IV Signal
35th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
35.4%
All Signals
- BEARISH: Price extended above range (+7.8% above its trading range)
- NEUTRAL: Options fairly priced (IV 35th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 106.1% below Wall St target ($77.56)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$29.28 -
$34.92
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.84
(15.5%)
Support & Resistance Levels
Support Level
$30.00
Resistance Level
$38.23
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.95
Wall Street Target
$77.56
(+106.1%)
Share & Embed Analysis
Last updated: August 23, 2026 6:32 AM ET
Data refreshes hourly during market hours. Next update: 7:32 AM
Data refreshes hourly during market hours. Next update: 7:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Marcella K Ruddy
SELL
1000 shares
2026-04-01
Marcella K Ruddy
SELL
10000 shares
2026-03-06
Peter Mcnamara
SELL
6262 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
